US drugmaker Regeneron Pharmaceuticals Inc. on Tuesday, has said it is now preparing to begin clinical trials by early-summer after identifying hundreds of antibodies that could treat or prevent the coronavirus disease 2019 (COVID-19).
The company said two antibodies will be selected to develop a "cocktail" and that it plans to begin large-scale manufacturing of the treatment by mid-April.
Regeneron aims to produce 200,000 doses per month by the end of summer.
It was in February when the company announced a partnership with the U.S. Department of Health and Human Services to develop a coronavirus treatment and said it would focus on monoclonal antibodies.
On the other hand, there are at least 12 other drugmakers who are currently working on vaccines, antivirals and other treatments to help fight against the pandemic, with some antivirals already being used in trials.
No comments:
Post a Comment